Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma (NASDAQ:SBFM) is the kind of company that keeps the market honest. On paper, it's small, barely a rounding error next to the giants of biotech. But size isn't the story here. Execution is. Sunshine has spent the past year building an engine that's starting to hum across multiple fronts: generics, biosimilars, mRNA cancer therapies, and antiviral research. And in the process, it's doing what small companies rarely do well: scale with discipline.

In Canada, Sunshine's Nora Pharma subsidiary has been quietly expanding its generics portfolio, stacking products that feed real, repeatable revenue. The launch of gabapentin, a generic version of Neurontin used for nerve pain, wasn't just another SKU- it marked SBFM's ability to execute on commercial distribution and regulatory follow-through. Each new product gives Nora a stronger foothold in Canada's growing generic pharmaceutical market, a region known for its efficiency, stability, and high barrier to entry. It also shows that Sunshine isn't building flash; it's building foundations.

And once those foundations were set, the company didn't wait to test its strength. On July 2, Sunshine launched NIOPEG^®, its biosimilar to Neulasta. That single event positioned the company in one of the most competitive arenas in the pharmaceutical industry-biologics. It's the first proof that Sunshine can transition from simple generics into complex molecules, a step that opens new revenue channels and higher margins. NIOPEG® doesn't just expand the company's catalog; it redefines its credibility.

Sunshine Biopharma by the Numbers: Growth

Sunshine's growth story isn't limited to labs and licensing. The company also strengthened its financial base by implementing a $5 million digital treasury asset, a forward-looking move designed to create long-term value while reducing reliance on traditional equity financing. The beauty of that decision isn't the size of the starting figure; it's the compounding potential.

Even moderate returns on that asset could help fund future growth initiatives while offsetting dilution, turning balance-sheet strategy into a growth engine. For Sunshine, it's a bold but disciplined step that demonstrates another dose of large-cap thinking in a microcap frame.

That discipline hasn't gone unnoticed. Aegis Capital recently reiterated its BUY rating and a $7.00 price target on Sunshine Biopharma, about 343% higher than its current $1.58, citing SBFM's strategic progress and balanced growth trajectory. It's a rare endorsement for a microcap that continues to prove it can move with institutional-grade precision.

That discipline is already showing up where it counts - in the numbers.

Revenue Engine Is Revving

First-quarter revenue reached $8.9 million, an 18% year-over-year jump. Gross profit came in at $2.73 million, a clear improvement that signals growing operational efficiency. The company kept its net loss to $1.18 million, impressive for a biotech still reinvesting heavily in R&D.

By the second quarter, revenue climbed again to $9.41 million. It's not a breakout yet, but it's steady. And that word-steady-is where confidence begins to build. Sunshine isn't sprinting toward a one-off therapeutic moonshot. It's pacing itself toward sustainable, repeatable growth that can scale over time.

Behind those numbers is where the ambition shows. Sunshine's mRNA-based cancer therapy, K1.1, is advancing through preclinical testing with results that are hard to ignore. The treatment reduced tumor growth in liver cancer models with strong tolerability-a combination that usually separates the promising from the possible. It's early data, but it's real data. That distinction matters. In a sector full of speculative storytelling, Sunshine's ability to back its headlines with measurable outcomes makes all the difference.

That same discipline is driving its antiviral research. Working with the University of Arizona, Sunshine is developing non-covalent PLpro protease inhibitors that show dose-dependent antiviral activity against SARS-CoV-2. It's not about chasing the next pandemic headline. It's about building a flexible technology platform that can adapt as fast as new viral threats emerge. That's how small biotech companies survive-by making agility their edge.

Creating Tangible Value Through a Deepening Pipeline

For partners and stakeholders, the appeal is balance. Sunshine has recurring revenue from generics to keep the lights bright, near-term growth from biosimilars, and long-term potential from its therapeutic pipeline. It's a layered model that most microcaps can't pull off. Each division reinforces the other, creating an ecosystem that can absorb setbacks while compounding wins. This is what happens when a company stops trying to look big and simply starts acting like it.

Sunshine Biopharma is reminding the market what the middle ground of biotech should look like-small enough to move fast, but established enough to deliver results that matter. It's not built on speculation dressed as ambition. It's built on progress-on tangible milestones that let stakeholders see success taking shape quarter after quarter. Sunshine isn't asking for imagination; it's providing evidence.

The best part of the Sunshine Biopharma story is that it's not betting on one breakthrough to define its future. It's building a business where proof is the story. That difference, especially in a sector dominated by hype cycles and billion-dollar budgets, is what makes Sunshine stand out. Its growth is steady, its science is advancing, and its leadership is turning potential into performance. It may trade like a microcap, but it's behaving like a contender. And that's the kind of contradiction the market never ignores for long.

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 72 generic prescription drugs on the market in Canada and more than 12 additional drugs planned to be launched in the remainder of 2025. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

All registered trademarks are the property of their respective owners.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

Forward-Looking Statements
This article was prepared by Hawk Point Media Group, LLC and may contain information, views, or opinions regarding the future expectations, plans, and prospects of Sunshine BioPharma, Inc.. that constitute or may constitute forward-looking statements. These statements are not historical facts and are based on assumptions, beliefs, and expectations regarding future economic and operating performance. Although Hawk Point Media Group, LLC believes such statements are made in good faith and based on information available at the time of writing, there can be no assurance that the expectations expressed will prove accurate. Sunshine BioPharma, Inc. and Hawk Point Media Group, LLC undertake no obligation to update or revise any forward-looking statements, except as required by applicable law.

Forward-looking statements are inherently subject to risks, uncertainties, and factors that could cause actual results to differ materially from those projected. Such factors include, but are not limited to, industry conditions, regulatory developments, economic trends, and risks identified in Sunshine BioPharma, Inc. filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of publication.

Accuracy & Disclosure Statement: Hawk Point Media Group, LLC ("HPM") operates on a fee-based, fixed-term retainer with Meza Media LLC to provide press-release, editorial, digital-media, and consulting services. Under this agreement, HPM is responsible for producing and publishing sponsored content. Meza Media LLC has paid HPM a fixed retainer, from which up to ten thousand U.S. dollars will be allocated toward the creation and syndication of content about Sunshine Biopharma, Inc. (NASDAQ:SBFM) for the period beginning October 14, 2025 and ending October 20, 2025. Due to this arrangement, this material should be considered sponsored content. The information contained herein is based on sources believed to be reliable, including publicly available filings, company disclosures, and direct website content, and is accurate to the best of our knowledge at the time of creation. This material may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties that could cause actual results to differ materially. Readers should not place undue reliance on such statements and should refer to the company's SEC filings for additional information. This content is for informational purposes only and should not be construed as investment, legal, or tax advice. Nothing herein constitutes a solicitation, recommendation, or offer to buy or sell any security. HPM is not a registered investment adviser or broker-dealer.

At the time of creation, HPM does not own, buy, sell, or trade securities of the companies covered, including Sunshine Biopharma, Inc. HPM will not receive award shares as compensation and will not purchase shares in the open market for Sunshine BioPharma, Inc. for a period of not less than thirty (30) days on either side of the engagement period. If HPM owns shares in a featured company prior to any services agreement, HPM agrees to either decline the engagement or divest all such shares at least five (5) days before any digital marketing program begins. Readers should assume that Meza Media LLC, its principals, or affiliates may own shares of the featured company and, at their sole discretion and without consultation with HPM, may sell some or all of those shares at any time, including during the campaign period.

Any reproduction or syndication of this content must include this disclosure. This statement is made pursuant to Section 17(b) of the Securities Act of 1933, the Federal Trade Commission's Endorsement Guides (16 CFR Part 255), and other applicable regulations governing sponsored investment communications.

For more information about this content, please contact: [email protected]

SOURCE: Sunshine Biopharma

View the original press release on ACCESS Newswire